Stryker Corporation is a medical technology company that provides innovative products and services to improve healthcare outcomes. It operates in the MedSurg and Neurotechnology, and Orthopaedics and Spine segments, which include surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The company has received favorable ratings from several brokerage firms, with the consensus rating currently at “Moderate Buy” and the average price target at $270.79. Stryker last announced its earnings results on Tuesday, January 31st, reporting $3.00 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.16. Additionally, the firm recently announced a quarterly dividend of $0.75 per share, payable on Friday, April 28th, to shareholders of record on Friday, March 31st. Insiders have sold 357,410 shares of company stock valued at $97,831,003. Company insiders own 6.70% of the company’s stock.
Gateway Investment Advisers LLC has increased its position in Stryker Co. by 3.5% in the fourth quarter, according to the latest Form 13F filing with the Securities and Exchange Commission. Other hedge funds have also modified their holdings of the medical technology company, including Vanguard Group, BlackRock Inc., Price T Rowe Associates Inc. MD, State Street Corp, and Fisher Asset Management LLC. Vanguard Group Inc. owns 29,795,845 shares of Stryker worth $6,034,850,000, BlackRock Inc. owns 23,659,084 shares worth $4,791,909,000, Price T Rowe Associates Inc. MD owns 20,129,316 shares worth $4,091,832,000, State Street Corp owns 14,052,691 shares worth $2,855,916,000, and Fisher Asset Management LLC owns 3,576,824 shares worth $724,450,000. Overall, institutional investors hold 77.10% of Stryker’s stock.
Stryker Co.’s stock is up 0.9%, trading at $276.69 as of Friday. The company has a market cap of $104.82 billion, with a 12-month low of $188.84 and a 12-month high of $284.00. Stryker has a P/E ratio of 44.84 and a beta of 0.93. Its current ratio is 1.63, and its quick ratio is 1.00, while its debt-to-equity ratio is 0.71. The company’s fifty-day simple moving average is $265.35, and its 200-day simple moving average is $240.75.
In its latest earnings results announcement on January 31st, Stryker exceeded expectations by posting earnings per share of $3.00, beating the consensus estimate of $2.84 by $0.16. Stryker’s revenue for the quarter was $5.20 billion, compared to the consensus estimate of $4.97 billion, representing a 10.7% increase year-over-year. The business had a net margin of 12.78% and a return on equity of 22.39%. In the same quarter of the previous year, the company posted earnings per share of $2.71. Analysts expect Stryker to post 10.02 EPS for the current year.
Several brokerages have given their opinion on SYK recently, including Wells Fargo & Company, Barclays, Royal Bank of Canada, Morgan Stanley, and Argus. The stock currently has a consensus rating of “Moderate Buy,” with seven investment analysts rating the stock as hold and thirteen as buy. The company’s consensus price target is $270.79, according to data from MarketBeat.
Additionally, Stryker recently announced a quarterly dividend on its common stock of $0.63 per share, payable on April 30th, 2021, to shareholders of record at the close of business on March 31st, 2021.
Stryker has announced a quarterly dividend of $0.75 per share, to be paid on April 28th, 2021, to shareholders of record on March 31st, 2021. This represents a $3.00 dividend on an annualized basis, with a yield of 1.08%. The ex-dividend date is March 30th, 2021, and Stryker’s dividend payout ratio (DPR) is 48.62%.
Insider selling has occurred at Stryker, with VP Robert S. Fletcher selling 3,000 shares of the company’s stock in a transaction on February 3rd, 2021, at an average price of $283.54 per share. Following this transaction, Fletcher now holds 6,636 shares of the company’s stock, valued at $1,881,571.44. In addition, CAO William E. Berry, Jr. sold 4,058 shares of the firm’s stock on February 2nd, 2021, at an average price of $279.79 per share, with a total value of $1,135,387.82. Following this transaction, Berry holds 2,886 shares in the company, valued at $807,473.94. In the last quarter, insiders at Stryker have sold 357,410 shares of company stock, valued at $97,831,003. Stryker’s insiders own 6.70% of the company’s stock.
Stryker Co.’s stock currently has a “Moderate Buy” rating, with a consensus price target of $270.79, according to data from MarketBeat.
Stryker Corp. is a leading medical technology company that offers advanced products and services to improve patient outcomes in the healthcare industry. The company operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments, offering a range of surgical equipment, communication systems, patient handling, intensive care disposable products, and more. Investors interested in tracking the performance of Stryker can visit HoldingsChannel.com to view the latest 13F filings and insider trades for the company. To receive the latest news and ratings for Stryker, investors can sign up for MarketBeat.com’s free daily email newsletter.
Don’t miss interesting posts on Famousbio
